{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T21:29:31Z","timestamp":1763414971129,"version":"3.45.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,17]]},"DOI":"10.7759\/cureus.97094","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T20:21:22Z","timestamp":1763410882000},"source":"Crossref","is-referenced-by-count":0,"title":["Prevalence of Non-alcoholic Fatty Liver Disease in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis"],"prefix":"10.7759","author":[{"given":"Anastasia","family":"Postoev","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abebe","family":"Yigzaw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helai","family":"Hussaini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olaniyi","family":"Fadeyi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rahman Hameed","family":"Mohammed Abdul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonalben","family":"Chaudhary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed Qasim","family":"Rauf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neelum","family":"Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi ZM","year":"2016","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016, 64:73-84. 10.1002\/hep.28431","journal-title":"Hepatology"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani N","year":"2018","unstructured":"Chalasani N, Younossi Z, Lavine JE, et al.. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018, 67:328-57. 10.1002\/hep.29367","journal-title":"Hepatology"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32448-0","article-title":"Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies","volume":"390","author":"Ng SC","year":"2017","unstructured":"Ng SC, Shi HY, Hamidi N, et al.. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017, 390:2769-78. 10.1016\/S0140-6736(17)32448-0","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2012.10.015","article-title":"Risk factors of non-alcoholic fatty liver disease in patients with inflammatory bowel disease","volume":"7","author":"Sourianarayanane A","year":"2013","unstructured":"Sourianarayanane A, Garg G, Smith TH, Butt MI, McCullough AJ, Shen B. Risk factors of non-alcoholic fatty liver disease in patients with inflammatory bowel disease. J Crohns Colitis. 2013, 7:e279-85. 10.1016\/j.crohns.2012.10.015","journal-title":"J Crohns Colitis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31518","article-title":"Multiple parallel hits hypothesis in nonalcoholic fatty liver disease: revisited after a decade","volume":"73","author":"Tilg H","year":"2021","unstructured":"Tilg H, Adolph TE, Moschen AR. Multiple parallel hits hypothesis in nonalcoholic fatty liver disease: revisited after a decade. Hepatology. 2021, 73:833-42. 10.1002\/hep.31518","journal-title":"Hepatology"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v24.i14.1491","article-title":"Nonalcoholic fatty liver disease and liver transplantation - where do we stand?","volume":"24","author":"Mikolasevic I","year":"2018","unstructured":"Mikolasevic I, Filipec-Kanizaj T, Mijic M, et al.. Nonalcoholic fatty liver disease and liver transplantation - where do we stand?. World J Gastroenterol. 2018, 24:1491-506. 10.3748\/wjg.v24.i14.1491","journal-title":"World J Gastroenterol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13265","article-title":"Hepatic manifestations of inflammatory bowel diseases","volume":"37","author":"Restellini S","year":"2017","unstructured":"Restellini S, Chazouill\u00e8res O, Frossard JL. Hepatic manifestations of inflammatory bowel diseases. Liver Int. 2017, 37:475-89. 10.1111\/liv.13265","journal-title":"Liver Int"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000001085","article-title":"Epidemiology and risk factors of nonalcoholic fatty liver disease among patients with inflammatory bowel disease","volume":"23","author":"Glassner K","year":"2017","unstructured":"Glassner K, Malaty HM, Abraham BP. Epidemiology and risk factors of nonalcoholic fatty liver disease among patients with inflammatory bowel disease. Inflamm Bowel Dis. 2017, 23:998-1003. 10.1097\/MIB.0000000000001085","journal-title":"Inflamm Bowel Dis"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izy051","article-title":"Nonalcoholic fatty liver disease in inflammatory bowel disease: prevalence and risk factors","volume":"24","author":"Principi M","year":"2018","unstructured":"Principi M, Iannone A, Losurdo G, et al.. Nonalcoholic fatty liver disease in inflammatory bowel disease: prevalence and risk factors. Inflamm Bowel Dis. 2018, 24:1589-96. 10.1093\/ibd\/izy051","journal-title":"Inflamm Bowel Dis"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1097\/00004836-200305000-00012","article-title":"Sonographic prevalence of liver steatosis and biliary tract stones in patients with inflammatory bowel disease: study of 511 subjects at a single center","volume":"36","author":"Bargiggia S","year":"2003","unstructured":"Bargiggia S, Maconi G, Elli M, et al.. Sonographic prevalence of liver steatosis and biliary tract stones in patients with inflammatory bowel disease: study of 511 subjects at a single center. J Clin Gastroenterol. 2003, 36:417-20. 10.1097\/00004836-200305000-00012","journal-title":"J Clin Gastroenterol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2012.04660.x","article-title":"Serum levels and mesenteric fat tissue expression of adiponectin and leptin in patients with Crohn's disease","volume":"170","author":"Rodrigues VS","year":"2012","unstructured":"Rodrigues VS, Milanski M, Fagundes JJ, et al.. Serum levels and mesenteric fat tissue expression of adiponectin and leptin in patients with Crohn's disease. Clin Exp Immunol. 2012, 170:358-64. 10.1111\/j.1365-2249.2012.04660.x","journal-title":"Clin Exp Immunol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000520","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"Rinella ME","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, et al.. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023, 78:1966-86. 10.1097\/HEP.0000000000000520","journal-title":"Hepatology"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-017-0124-2","article-title":"Non-alcoholic fatty liver disease phenotypes in patients with inflammatory bowel disease","volume":"9","author":"Sartini A","year":"2018","unstructured":"Sartini A, Gitto S, Bianchini M, et al.. Non-alcoholic fatty liver disease phenotypes in patients with inflammatory bowel disease. Cell Death Dis. 2018, 9:87. 10.1038\/s41419-017-0124-2","journal-title":"Cell Death Dis"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/apt.16703","article-title":"Systematic review with meta-analysis: environmental and dietary differences of inflammatory bowel disease in Eastern and Western populations","volume":"55","author":"Zhao M","year":"2022","unstructured":"Zhao M, Feng R, Ben-Horin S, et al.. Systematic review with meta-analysis: environmental and dietary differences of inflammatory bowel disease in Eastern and Western populations. Aliment Pharmacol Ther. 2022, 55:266-76. 10.1111\/apt.16703","journal-title":"Aliment Pharmacol Ther"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref16","unstructured":"The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. (2011). Accessed. November 2025: https:\/\/www.evidencebasedpublichealth.de\/download\/Newcastle_Ottowa_Scale_Pope_Bruce.pdf."},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3390\/life14101226","article-title":"Metabolic dysfunction-associated steatotic liver disease in patients with inflammatory bowel diseases: a pilot study","volume":"14","author":"Abenavoli L","year":"2024","unstructured":"Abenavoli L, Spagnuolo R, Scarlata GG, Gambardella ML, Boccuto L, M\u00e9ndez-S\u00e1nchez N, Luzza F. Metabolic dysfunction-associated steatotic liver disease in patients with inflammatory bowel diseases: a pilot study. Life (Basel). 2024, 14:10.3390\/life14101226","journal-title":"Life (Basel)"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.14740\/gr1509","article-title":"Burden and predictors of non-alcoholic fatty liver disease in a retrospective cohort of patients with Crohn\u2019s disease","volume":"15","author":"Abomhya A","year":"2022","unstructured":"Abomhya A, Mahmoodurrahman M, Ayaz S, Hamad H, Khan F. Burden and predictors of non-alcoholic fatty liver disease in a retrospective cohort of patients with Crohn\u2019s disease. Gastroenterology Res. 2022, 15:82-90. 10.14740\/gr1509","journal-title":"Gastroenterology Res"},{"key":"ref19","article-title":"Non-alcoholic fatty liver disease among patients with inflammatory bowel disease in Qatar: prevalence and risk factors","volume":"3","author":"Almohannadi M","year":"2020","unstructured":"Almohannadi M, Chandra P, Varughese B, et al.. Non-alcoholic fatty liver disease among patients with inflammatory bowel disease in Qatar: prevalence and risk factors. Open J Gastroenterol Hepatol. 2020, 3:","journal-title":"Open J Gastroenterol Hepatol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjx002.448","article-title":"P323 Fatty liver assessment in inflammatory bowel disease patients using controlled attenuation parameter","volume":"11","author":"Balaban DV","year":"2017","unstructured":"Balaban DV, Popp A, Robu G, et al.. P323 Fatty liver assessment in inflammatory bowel disease patients using controlled attenuation parameter. Journal of Crohn's and Colitis. 2017, 11:240-1. 10.1093\/ecco-jcc\/jjx002.448","journal-title":"Journal of Crohn's and Colitis"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000000832","article-title":"Incidence and predictors of nonalcoholic fatty liver disease by serum biomarkers in patients with inflammatory bowel disease","volume":"22","author":"Bessissow T","year":"2016","unstructured":"Bessissow T, Le NH, Rollet K, Afif W, Bitton A, Sebastiani G. Incidence and predictors of nonalcoholic fatty liver disease by serum biomarkers in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2016, 22:1937-44. 10.1097\/MIB.0000000000000832","journal-title":"Inflamm Bowel Dis"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2017.09.008","article-title":"Primary sclerosing cholangitis is protective against nonalcoholic fatty liver disease in inflammatory bowel disease","volume":"69","author":"Bosch DE","year":"2017","unstructured":"Bosch DE, Yeh MM. Primary sclerosing cholangitis is protective against nonalcoholic fatty liver disease in inflammatory bowel disease. Hum Pathol. 2017, 69:55-62. 10.1016\/j.humpath.2017.09.008","journal-title":"Hum Pathol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10143062","article-title":"Insulin resistance is not increased in inflammatory bowel disease patients but is related to non-alcoholic fatty liver disease","volume":"10","author":"Carrillo-Palau M","year":"2021","unstructured":"Carrillo-Palau M, Hern\u00e1ndez-Camba A, Hern\u00e1ndez Alvarez-Buylla N, et al.. Insulin resistance is not increased in inflammatory bowel disease patients but is related to non-alcoholic fatty liver disease. J Clin Med. 2021, 10:10.3390\/jcm10143062","journal-title":"J Clin Med"},{"key":"ref24","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjae190.0601","article-title":"P0427 Nutritional factors associated with the presence of non-alcoholic fatty liver disease (NAFLD) in patients with inflammatory bowel disease (IBD)","volume":"19","author":"Castelhano NS","year":"2025","unstructured":"Castelhano NS, Oliveira EC, Lopes MA, et al.. P0427 Nutritional factors associated with the presence of non-alcoholic fatty liver disease (NAFLD) in patients with inflammatory bowel disease (IBD). Journal of Crohn's and Colitis. 2025, 19:","journal-title":"Journal of Crohn's and Colitis"},{"key":"ref25","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjab232.290","article-title":"P162 Prevalence and incidence of nonalcoholic fatty liver disease in Inflammatory Bowel Disease patients: risk factors for progression","volume":"16","author":"Crispino F","year":"2022","unstructured":"Crispino F, Brinch D, Scrivo B, et al.. P162 Prevalence and incidence of nonalcoholic fatty liver disease in Inflammatory Bowel Disease patients: risk factors for progression. Journal of Crohn's and Colitis. 2022, 16:","journal-title":"Journal of Crohn's and Colitis"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjy222.872","article-title":"Retrospective study on incidence rates of NAFLD and advanced liver fibrosis in Crohn\u2019s disease and ulcerative colitis","volume":"13","author":"Domislovic V","year":"20191","unstructured":"Domislovic V, Stromar IK, Premuzic M, et al.. Retrospective study on incidence rates of NAFLD and advanced liver fibrosis in Crohn\u2019s disease and ulcerative colitis. J Crohns Colitis. 20191, 13:496. 10.1093\/ecco-jcc\/jjy222.872","journal-title":"J Crohns Colitis"},{"key":"ref27","article-title":"Prevalence of non-alcoholic steatohepatitis (NASH) in individuals with crohn's disease: a population-based national study: 854","volume":"113","author":"Elchert JA","year":"2018","unstructured":"Elchert JA, Mansoor E, Sinh P, et al.. Prevalence of non-alcoholic steatohepatitis (NASH) in individuals with crohn's disease: a population-based national study: 854. Am J Gastroenterol. 2018, 113:476-7.","journal-title":"Am J Gastroenterol"},{"key":"ref28","article-title":"Prevalence of non-alcoholic steatohepatitis (NASH) in individuals with ulcerative colitis: a population-based national study: 855","volume":"113","author":"Elchert JA","year":"2018","unstructured":"Elchert JA, Mansoor E, Sinh P, et al.. Prevalence of non-alcoholic steatohepatitis (NASH) in individuals with ulcerative colitis: a population-based national study: 855. Am J Gastroenterol. 2018, 113:477.","journal-title":"Am J Gastroenterol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v26.i46.7367","article-title":"Prevalence and risk factors of nonalcoholic fatty liver disease in patients with inflammatory bowel diseases: a cross-sectional and longitudinal analysis","volume":"26","author":"Hoffmann P","year":"2020","unstructured":"Hoffmann P, Jung V, Behnisch R, Gauss A. Prevalence and risk factors of nonalcoholic fatty liver disease in patients with inflammatory bowel diseases: a cross-sectional and longitudinal analysis. World J Gastroenterol. 2020, 26:7367-81. 10.3748\/wjg.v26.i46.7367","journal-title":"World J Gastroenterol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.5009\/gnl220409","article-title":"Hepatic steatosis but not fibrosis is independently associated with poor outcomes in patients with inflammatory bowel disease","volume":"18","author":"Hyun HK","year":"2024","unstructured":"Hyun HK, Lee HW, Park J, et al.. Hepatic steatosis but not fibrosis is independently associated with poor outcomes in patients with inflammatory bowel disease. Gut Liver. 2024, 18:294-304. 10.5009\/gnl220409","journal-title":"Gut Liver"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1186\/s43162-025-00470-5","article-title":"Prevalence of metabolic dysfunction-associated steatotic liver disease in inflammatory bowel disease patients: an Egyptian cross-sectional study","volume":"37","author":"Kamel SY","year":"2025","unstructured":"Kamel SY, Sakr MA, Hamed W, et al.. Prevalence of metabolic dysfunction-associated steatotic liver disease in inflammatory bowel disease patients: an Egyptian cross-sectional study. Egyp J Int Med. 2025, 37:82. 10.1186\/s43162-025-00470-5","journal-title":"Egyp J Int Med"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1159\/000506938","article-title":"Sarcopenia is a new risk factor of nonalcoholic fatty liver disease in patients with inflammatory bowel disease","volume":"38","author":"Kang MK","year":"2020","unstructured":"Kang MK, Kim KO, Kim MC, Park JG, Jang BI. Sarcopenia is a new risk factor of nonalcoholic fatty liver disease in patients with inflammatory bowel disease. Dig Dis. 2020, 38:507-14. 10.1159\/000506938","journal-title":"Dig Dis"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.5472\/marumj.570907","article-title":"Prevalence of fatty liver disease in patients with inflammatory bowel disease: a transient elastography study on the basis of a controlled attenuation parameter","volume":"32","author":"Kani HT","year":"2019","unstructured":"Kani HT, Deliktas I, Yilmaz Y. Prevalence of fatty liver disease in patients with inflammatory bowel disease: a transient elastography study on the basis of a controlled attenuation parameter. Marmara Medical Journal. 2019, 32:68-70. 10.5472\/marumj.570907","journal-title":"Marmara Medical Journal"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjx002.460","article-title":"P335 Prevalence and risk factors for non alcoholic fatty liver disease in inflammatory bowel disease","volume":"11","author":"Iannone A","year":"2017","unstructured":"Iannone A, Losurdo G, Shahini E, et al.. P335 Prevalence and risk factors for non alcoholic fatty liver disease in inflammatory bowel disease. Journal of Crohn's and Colitis. 2017, 11:247-8. 10.1093\/ecco-jcc\/jjx002.460","journal-title":"Journal of Crohn's and Colitis"},{"key":"ref35","article-title":"High incidence of non-alcoholic fatty liver disease in patients with Crohn\u2019s disease but not ulcerative colitis","volume":"10","author":"Li D","year":"2017","unstructured":"Li D, Lu C, Yu C. High incidence of non-alcoholic fatty liver disease in patients with Crohn\u2019s disease but not ulcerative colitis. Int J Clin Exp Pathol. 2017, 10:10633-9.","journal-title":"Int J Clin Exp Pathol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.20524\/aog.2019.0371","article-title":"Prevalence of non-alcoholic fatty liver disease on computed tomography in patients with inflammatory bowel disease visiting an emergency department","volume":"32","author":"Likhitsup A","year":"2019","unstructured":"Likhitsup A, Dundulis J, Ansari S, et al.. Prevalence of non-alcoholic fatty liver disease on computed tomography in patients with inflammatory bowel disease visiting an emergency department. Ann Gastroenterol. 2019, 32:283-6. 10.20524\/aog.2019.0371","journal-title":"Ann Gastroenterol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.14309\/01.ajg.0000798780.14901.4e","article-title":"P045 Prevalence of non-alcoholic fatty liver disease (NAFLD) in patients with inflammatory bowel disease (IBD) in a Brazilian public healthcare clinic","volume":"116","author":"Lopes M","year":"2021","unstructured":"Lopes M, Shintaku D, de Oliveira AC, et al.. P045 Prevalence of non-alcoholic fatty liver disease (NAFLD) in patients with inflammatory bowel disease (IBD) in a Brazilian public healthcare clinic. Am J Gastroenterol. 2021, 116:S11-2. 10.14309\/01.ajg.0000798780.14901.4e","journal-title":"Am J Gastroenterol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v25.i37.5676","article-title":"Nonalcoholic fatty liver disease in patients with inflammatory bowel disease: beyond the natural history","volume":"25","author":"Magr\u00ec S","year":"2019","unstructured":"Magr\u00ec S, Paduano D, Chicco F, et al.. Nonalcoholic fatty liver disease in patients with inflammatory bowel disease: beyond the natural history. World J Gastroenterol. 2019, 25:5676-86. 10.3748\/wjg.v25.i37.5676","journal-title":"World J Gastroenterol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2023.10.019","article-title":"Crohn\u00b4s disease is an independent risk factor for liver fibrosis in patients with inflammatory bowel disease and non-alcoholic fatty liver disease","volume":"120","author":"Mart\u00ednez-Dom\u00ednguez SJ","year":"2024","unstructured":"Mart\u00ednez-Dom\u00ednguez SJ, Garc\u00eda-Mateo S, Gargallo-Puyuelo CJ, et al.. Crohn\u00b4s disease is an independent risk factor for liver fibrosis in patients with inflammatory bowel disease and non-alcoholic fatty liver disease. Eur J Intern Med. 2024, 120:99-106. 10.1016\/j.ejim.2023.10.019","journal-title":"Eur J Intern Med"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izz324","article-title":"Derivation and internal validation of a clinical prediction tool to predict nonalcoholic fatty liver disease in patients with Crohn\u2019s disease","volume":"26","author":"McHenry S","year":"2020","unstructured":"McHenry S, Tirath A, Tsai R, et al.. Derivation and internal validation of a clinical prediction tool to predict nonalcoholic fatty liver disease in patients with Crohn\u2019s disease. Inflamm Bowel Dis. 2020, 26:1917-25. 10.1093\/ibd\/izz324","journal-title":"Inflamm Bowel Dis"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.35854","article-title":"Increased risk of non-alcoholic steatohepatitis in patients with inflammatory bowel disease: a population-based study","volume":"15","author":"Onwuzo S","year":"2023","unstructured":"Onwuzo S, Boustany A, Saleh M, et al.. Increased risk of non-alcoholic steatohepatitis in patients with inflammatory bowel disease: a population-based study. Cureus. 2023, 15:e35854. 10.7759\/cureus.35854","journal-title":"Cureus"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izy200","article-title":"Screening for nonalcoholic fatty liver disease in inflammatory bowel diseases: a cohort study using transient elastography","volume":"25","author":"Saroli Palumbo C","year":"2019","unstructured":"Saroli Palumbo C, Restellini S, Chao CY, et al.. Screening for nonalcoholic fatty liver disease in inflammatory bowel diseases: a cohort study using transient elastography. Inflamm Bowel Dis. 2019, 25:124-33. 10.1093\/ibd\/izy200","journal-title":"Inflamm Bowel Dis"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-020-06588-6","article-title":"Nonalcoholic fatty liver disease is common in IBD patients however progression to hepatic fibrosis by noninvasive markers is rare","volume":"66","author":"Ritaccio G","year":"2021","unstructured":"Ritaccio G, Stoleru G, Abutaleb A, Cross RK, Shetty K, Sakiani S, Wong U. Nonalcoholic fatty liver disease is common in IBD patients however progression to hepatic fibrosis by noninvasive markers is rare. Dig Dis Sci. 2021, 66:3186-91. 10.1007\/s10620-020-06588-6","journal-title":"Dig Dis Sci"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2022.01.039","article-title":"Increased risk of MAFLD and liver fibrosis in inflammatory bowel disease independent of classic metabolic risk factors","volume":"21","author":"Rodriguez-Duque JC","year":"2023","unstructured":"Rodriguez-Duque JC, Calleja JL, Iruzubieta P, et al.. Increased risk of MAFLD and liver fibrosis in inflammatory bowel disease independent of classic metabolic risk factors. Clin Gastroenterol Hepatol. 2023, 21:406-414.e7. 10.1016\/j.cgh.2022.01.039","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.12828","article-title":"Significance of non-alcoholic fatty liver disease in Crohn's disease: a retrospective cohort study","volume":"47","author":"Sagami S","year":"2017","unstructured":"Sagami S, Ueno Y, Tanaka S, et al.. Significance of non-alcoholic fatty liver disease in Crohn's disease: a retrospective cohort study. Hepatol Res. 2017, 47:872-81. 10.1111\/hepr.12828","journal-title":"Hepatol Res"},{"key":"ref46","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjz203.291","article-title":"P162 Prevalence of NAFLD (non alcoholic fatty liver disease) and fibrosis in inflammatory bowel disease: the impact of traditional risk factors, intestinal inflammation and genetic phenotype","volume":"14","author":"Scrivo B","year":"2020","unstructured":"Scrivo B, Celsa C, Busacca A, et al.. P162 Prevalence of NAFLD (non alcoholic fatty liver disease) and fibrosis in inflammatory bowel disease: the impact of traditional risk factors, intestinal inflammation and genetic phenotype. Journal of Crohn's and Colitis. 2020, 14:219-20.","journal-title":"Journal of Crohn's and Colitis"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izy128","article-title":"IRGM gene variants modify the relationship between visceral adipose tissue and NAFLD in patients with Crohn\u2019s disease","volume":"24","author":"Simon TG","year":"2018","unstructured":"Simon TG, Van Der Sloot KW, Chin SB, et al.. IRGM gene variants modify the relationship between visceral adipose tissue and NAFLD in patients with Crohn\u2019s disease. Inflamm Bowel Dis. 2018, 24:2247-57. 10.1093\/ibd\/izy128","journal-title":"Inflamm Bowel Dis"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000003067","article-title":"Prevalence and risk factors of metabolic dysfunction-associated steatotic liver disease in patients with inflammatory bowel disease","author":"Tamimi TA","year":"2025","unstructured":"Tamimi TA, Abu-Farsakh N, AlRyalat SA, et al.. Prevalence and risk factors of metabolic dysfunction-associated steatotic liver disease in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2025, 10.1097\/MEG.0000000000003067","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11195959","article-title":"Screening for liver steatosis and fibrosis in patients with inflammatory bowel disease using vibration controlled transient elastography with controlled attenuation parameter","volume":"11","author":"Trifan A","year":"2022","unstructured":"Trifan A, Stafie R, Rotaru A, et al.. Screening for liver steatosis and fibrosis in patients with inflammatory bowel disease using vibration controlled transient elastography with controlled attenuation parameter. J Clin Med. 2022, 11:10.3390\/jcm11195959","journal-title":"J Clin Med"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11092623","article-title":"Hepatic steatosis and fibrosis in chronic inflammatory bowel disease","volume":"11","author":"Veltkamp C","year":"2022","unstructured":"Veltkamp C, Lan S, Korompoki E, Weiss KH, Schmidt H, Seitz HK. Hepatic steatosis and fibrosis in chronic inflammatory bowel disease. J Clin Med. 2022, 11:10.3390\/jcm11092623","journal-title":"J Clin Med"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0252286","article-title":"Evaluation of non-alcoholic fatty liver disease in patients with inflammatory bowel disease using controlled attenuation parameter technology: a Taiwanese retrospective cohort study","volume":"16","author":"Yen HH","year":"2021","unstructured":"Yen HH, Su PY, Huang SP, Wu L, Hsu TC, Zeng YH, Chen YY. Evaluation of non-alcoholic fatty liver disease in patients with inflammatory bowel disease using controlled attenuation parameter technology: a Taiwanese retrospective cohort study. PLoS One. 2021, 16:e0252286. 10.1371\/journal.pone.0252286","journal-title":"PLoS One"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1111\/apt.16879","article-title":"Meta-analysis: prevalence of, and risk factors for, non-alcoholic fatty liver disease in patients with inflammatory bowel disease","volume":"55","author":"Zamani M","year":"2022","unstructured":"Zamani M, Alizadeh-Tabari S, Singh S, Loomba R. Meta-analysis: prevalence of, and risk factors for, non-alcoholic fatty liver disease in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2022, 55:894-907. 10.1111\/apt.16879","journal-title":"Aliment Pharmacol Ther"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izaa189","article-title":"Prevalence of nonalcoholic fatty liver disease in patients with inflammatory bowel disease: a systematic review and meta-analysis","volume":"27","author":"Lin A","year":"2021","unstructured":"Lin A, Roth H, Anyane-Yeboa A, Rubin DT, Paul S. Prevalence of nonalcoholic fatty liver disease in patients with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis. 2021, 27:947-55. 10.1093\/ibd\/izaa189","journal-title":"Inflamm Bowel Dis"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izz043","article-title":"Systematic review with meta-analysis: epidemiology of nonalcoholic fatty liver disease in patients with inflammatory bowel disease","volume":"25","author":"Zou ZY","year":"2019","unstructured":"Zou ZY, Shen B, Fan JG. Systematic review with meta-analysis: epidemiology of nonalcoholic fatty liver disease in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2019, 25:1764-72. 10.1093\/ibd\/izz043","journal-title":"Inflamm Bowel Dis"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v22.i34.7727","article-title":"Co-existence of non-alcoholic fatty liver disease and inflammatory bowel disease: a review article","volume":"22","author":"Chao CY","year":"2016","unstructured":"Chao CY, Battat R, Al Khoury A, Restellini S, Sebastiani G, Bessissow T. Co-existence of non-alcoholic fatty liver disease and inflammatory bowel disease: a review article. World J Gastroenterol. 2016, 22:7727-34. 10.3748\/wjg.v22.i34.7727","journal-title":"World J Gastroenterol"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v19.i42.7327","article-title":"Hepatobiliary manifestations in inflammatory bowel disease: the gut, the drugs and the liver","volume":"19","author":"Rojas-Feria M","year":"2013","unstructured":"Rojas-Feria M, Castro M, Su\u00e1rez E, Ampuero J, Romero-G\u00f3mez M. Hepatobiliary manifestations in inflammatory bowel disease: the gut, the drugs and the liver. World J Gastroenterol. 2013, 19:7327-40. 10.3748\/wjg.v19.i42.7327","journal-title":"World J Gastroenterol"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.12073","article-title":"Decreased abundance of Faecalibacterium prausnitzii in the gut microbiota of Crohn's disease","volume":"28","author":"Fujimoto T","year":"2013","unstructured":"Fujimoto T, Imaeda H, Takahashi K, Kasumi E, Bamba S, Fujiyama Y, Andoh A. Decreased abundance of Faecalibacterium prausnitzii in the gut microbiota of Crohn's disease. J Gastroenterol Hepatol. 2013, 28:613-9. 10.1111\/jgh.12073","journal-title":"J Gastroenterol Hepatol"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-019-09987-8","article-title":"Significant decrease in Faecalibacterium among gut microbiota in nonalcoholic fatty liver disease: a large BMI- and sex-matched population study","volume":"13","author":"Iino C","year":"2019","unstructured":"Iino C, Endo T, Mikami K, et al.. Significant decrease in Faecalibacterium among gut microbiota in nonalcoholic fatty liver disease: a large BMI- and sex-matched population study. Hepatol Int. 2019, 13:748-56. 10.1007\/s12072-019-09987-8","journal-title":"Hepatol Int"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-010-0368-4","article-title":"Comparison of the fecal microbiota profiles between ulcerative colitis and Crohn's disease using terminal restriction fragment length polymorphism analysis","volume":"46","author":"Andoh A","year":"2011","unstructured":"Andoh A, Imaeda H, Aomatsu T, et al.. Comparison of the fecal microbiota profiles between ulcerative colitis and Crohn's disease using terminal restriction fragment length polymorphism analysis. J Gastroenterol. 2011, 46:479-86. 10.1007\/s00535-010-0368-4","journal-title":"J Gastroenterol"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1038\/srep08096","article-title":"Dysbiosis gut microbiota associated with inflammation and impaired mucosal immune function in intestine of humans with non-alcoholic fatty liver disease","volume":"5","author":"Jiang W","year":"2015","unstructured":"Jiang W, Wu N, Wang X, et al.. Dysbiosis gut microbiota associated with inflammation and impaired mucosal immune function in intestine of humans with non-alcoholic fatty liver disease. Sci Rep. 2015, 5:8096. 10.1038\/srep08096","journal-title":"Sci Rep"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1590\/s0004-28032012000100015","article-title":"Metabolic syndrome and risk factors for non-alcoholic fatty liver disease","volume":"49","author":"Souza MR","year":"2012","unstructured":"Souza MR, Diniz Mde F, Medeiros-Filho JE, Ara\u00fajo MS. Metabolic syndrome and risk factors for non-alcoholic fatty liver disease. Arq Gastroenterol. 2012, 49:89-96. 10.1590\/s0004-28032012000100015","journal-title":"Arq Gastroenterol"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.20294","article-title":"Trends in Liver Disease Etiology Among Adults Awaiting Liver Transplantation in the United States, 2014-2019","volume":"3","author":"Wong RJ","year":"2020","unstructured":"Wong RJ, Singal AK. Trends in Liver Disease Etiology Among Adults Awaiting Liver Transplantation in the United States, 2014-2019. JAMA Netw Open. 2020, 3:e1920294. 10.1001\/jamanetworkopen.2019.20294","journal-title":"JAMA Netw Open"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/427600-prevalence-of-non-alcoholic-fatty-liver-disease-in-patients-with-inflammatory-bowel-disease-a-systematic-review-and-meta-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T20:21:24Z","timestamp":1763410884000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/427600-prevalence-of-non-alcoholic-fatty-liver-disease-in-patients-with-inflammatory-bowel-disease-a-systematic-review-and-meta-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,17]]},"references-count":62,"URL":"https:\/\/doi.org\/10.7759\/cureus.97094","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,17]]}}}